{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:41:54Z","timestamp":1787506914043,"version":"build-2736575974"},"reference-count":29,"publisher":"Japan Endocrine Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1507\/endocrj.ej23-0378","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T17:12:03Z","timestamp":1706634723000},"page":"363-371","source":"Crossref","is-referenced-by-count":4,"title":["Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib"],"prefix":"10.1507","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5475-9309","authenticated-orcid":false,"given":"Naoki","family":"Fukuda","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan"},{"name":"Department of Clinical Cancer Genomics, Hokkaido University Graduate School of Medicine, Sapporo 060-0814, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Toda","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Suto","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Oki","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1471-4560","authenticated-orcid":false,"given":"Xiaofei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Urasaki","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4145-8694","authenticated-orcid":false,"given":"Yasuyoshi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan"},{"name":"Department of Chemotherapy and Cancer Center, The University of Tokyo Hospital, Tokyo 113-8655, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3721-004X","authenticated-orcid":false,"given":"Kenji","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-5183","authenticated-orcid":false,"given":"Junichi","family":"Tomomatsu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Mitani","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, et al. (2008) Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 <i>via<\/i> inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 14: 5459\u20135465.","DOI":"10.1158\/1078-0432.CCR-07-5270"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, et al. (2008) E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 122: 664\u2013671.","DOI":"10.1002\/ijc.23131"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Okamoto K, Kodama K, Takase K, Sugi NH, Yamamoto Y, et al. (2013) Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett 340: 97\u2013103.","DOI":"10.1016\/j.canlet.2013.07.007"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, et al. (2015) Lenvatinib <i>versus<\/i> placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372: 621\u2013630.","DOI":"10.1056\/NEJMoa1406470"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5 Kudo M, Finn RS, Qin S, Han KH, Ikeda K, et al. (2018) Lenvatinib <i>versus<\/i> sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391: 1163\u20131173.","DOI":"10.1016\/S0140-6736(18)30207-1"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Motzer R, Alekseev B, Rha SY, Porta C, Eto M, et al. (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 384: 1289\u20131300.","DOI":"10.1056\/NEJMoa2035716"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Makker V, Colombo N, Casado Herr\u00e1ez A, Santin AD, Colomba E, et al. (2022) Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med 386: 437\u2013448.","DOI":"10.1056\/NEJMoa2108330"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Hayman SR, Leung N, Grande JP, Garovic VD (2012) VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep 14: 285\u2013294.","DOI":"10.1007\/s11912-012-0242-z"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Kiyota N, Schlumberger M, Muro K, Ando Y, Takahashi S, et al. (2015) Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci 106: 1714\u20131721.","DOI":"10.1111\/cas.12826"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Iseki K, Ikemiya Y, Iseki C, Takishita S (2003) Proteinuria and the risk of developing end-stage renal disease. Kidney Int 63: 1468\u20131474.","DOI":"10.1046\/j.1523-1755.2003.00868.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Atkins RC, Briganti EM, Lewis JB, Hunsicker LG, Braden G, et al. (2005) Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 45: 281\u2013287.","DOI":"10.1053\/j.ajkd.2004.10.019"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Nagata M, Ninomiya T, Kiyohara Y, Murakami Y, Irie F, et al. (2013) Prediction of cardiovascular disease mortality by proteinuria and reduced kidney function: pooled analysis of 39,000 individuals from 7 cohort studies in Japan. Am J Epidemiol 178: 1\u201311.","DOI":"10.1093\/aje\/kws447"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Takahashi D, Nagahama K, Tsuura Y, Tanaka H, Tamura T (2012) Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction. Clin Exp Nephrol 16: 310\u2013315.","DOI":"10.1007\/s10157-011-0543-9"},{"key":"14","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1186\/s12885-021-08622-w","volume":"21","author":"C Masaki","year":"2021","unstructured":"14 Masaki C, Sugino K, Kobayashi S, Hosoi Y, Ono R, et al. (2021) Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients. BMC Cancer 21: 894.","journal-title":"BMC Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/1471-2407","issn-type":"print"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228\u2013247.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, et al. (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982\u2013992.","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48: 452\u2013458.","DOI":"10.1038\/bmt.2012.244"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Eba J, Nakamura K (2022) Overview of the ethical guidelines for medical and biological research involving human subjects in Japan. Jpn J Clin Oncol 52: 539\u2013544.","DOI":"10.1093\/jjco\/hyac034"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Kunz R, Friedrich C, Wolbers M, Mann JF (2008) Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148: 30\u201348.","DOI":"10.7326\/0003-4819-148-1-200801010-00190"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Ikesue H, Yamaoka K, Matsumoto A, Hirabatake M, Muroi N, et al. (2022) Risk factors of proteinuria and potentially protective effect of renin-angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib. Cancer Chemother Pharmacol 89: 833\u2013838.","DOI":"10.1007\/s00280-022-04408-4"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Kamba T, McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96: 1788\u20131795.","DOI":"10.1038\/sj.bjc.6603813"},{"key":"22","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/s12885-022-09611-3","volume":"22","author":"M Nakamura","year":"2022","unstructured":"22 Nakamura M, Funakoshi T, Kataoka S, Horimatsu T, Nishikawa Y, et al. (2022) Decision making for anti-VEGF inhibitor continuation: dip stick? or urine protein\/creatinine ratio? (VERSiON UP study). BMC Cancer 22: 515.","journal-title":"BMC Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/1471-2407","issn-type":"print"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Tahara M, Brose MS, Wirth LJ, Suzuki T, Miyagishi H, et al. (2019) Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer 106: 61\u201368.","DOI":"10.1016\/j.ejca.2018.10.002"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Sorich MJ, Rowland A, Kichenadasse G, Woodman RJ, Mangoni AA (2016) Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data. Br J Cancer 114: 1313\u20131317.","DOI":"10.1038\/bjc.2016.147"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Feliu J, Salud A, Safont MJ, Garc\u00eda-Gir\u00f3n C, Aparicio J, et al. (2015) Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer. PLoS One 10: e0116527.","DOI":"10.1371\/journal.pone.0116527"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26 Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, et al. (2005) Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 28: 164\u2013176.","DOI":"10.2337\/diacare.28.1.164"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Ramirez SP, McClellan W, Port FK, Hsu SI (2002) Risk factors for proteinuria in a large, multiracial, southeast Asian population. J Am Soc Nephrol 13: 1907\u20131917.","DOI":"10.1097\/01.ASN.0000018406.20282.C8"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Metcalfe W (2007) How does early chronic kidney disease progress? A background paper prepared for the UK Consensus Conference on early chronic kidney disease. Nephrol Dial Transplant 22 Suppl 9: ix26\u2013ix30.","DOI":"10.1093\/ndt\/gfm446"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Shibutani Y, Suzuki S, Sagara A, Enokida T, Okano S, et al. (2023) Impact of lenvatinib-induced proteinuria and renal dysfunction in patients with thyroid cancer. Front Oncol 13: 1154771.","DOI":"10.3389\/fonc.2023.1154771"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/71\/4\/71_EJ23-0378\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T00:11:10Z","timestamp":1714781470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/71\/4\/71_EJ23-0378\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej23-0378","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"EJ23-0378"}}